Advancements in Retinoblastoma Treatment: Unraveling the Potential of Intravitreal Chemotherapy.

advanced therapies chemoreduction global collaboration intra-vitreal chemotherapy intravitreal melphalan ocular toxicity pediatric cancer retinoblastoma targeted therapies treatment outcomes

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Jan 2024
Historique:
accepted: 26 01 2024
medline: 27 2 2024
pubmed: 27 2 2024
entrez: 27 2 2024
Statut: epublish

Résumé

Retinoblastoma necessitates urgent attention due to its potential fatality if untreated. Multiple treatment options are available and should be employed according to size, location, and the extent of dissemination. This review emphasizes the need for increased awareness, advanced diagnostic tools, and innovative treatment approaches, especially intravitreal chemotherapy (IVitC) to address the diverse manifestations and aggressive nature of retinoblastoma. Timely diagnosis and commitment to treatment are pivotal, as delays and reluctance to undergo enucleation contribute to unfavorable outcomes. The evolving treatment landscape, spanning from traditional interventions to modern targeted therapies such as intravitreal melphalan, holds promise for improved outcomes. While the intravitreal approach presents challenges, ongoing research aims to establish its definitive role in retinoblastoma treatment. In the treatment of retinoblastoma, IVitC raises considerations about side effects. The risk of tumor spread beyond the eye is rare, emphasising the potential of IVitC in carefully selected cases. Intravitreal injections exhibit fewer local adverse effects compared to intra-arterial chemotherapy, with careful measures reducing significant ocular complications. The evaluation of ocular toxicity, particularly with melphalan, underscores the importance of a nuanced approach to achieve the right balance between therapeutic efficacy and ocular safety. This comprehensive analysis of studies on IVitC and its ocular and systemic complications provides valuable insights for enhanced patient care. The review concludes with a focus on balancing safety and efficacy in local chemotherapeutic drugs, highlighting the need for thoughtful measures and continued research to optimise treatment modalities globally.

Identifiants

pubmed: 38410326
doi: 10.7759/cureus.53012
pmc: PMC10895558
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e53012

Informations de copyright

Copyright © 2024, Tanveer et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Shafiq Tanveer (S)

Ophthalmology, Khyber Teaching Hospital MTI, Peshawar, PAK.

Fahad Zafar (F)

Ophthalmology, Khyber Teaching Hospital MTI, Peshawar, PAK.

Hafsa Bibi (H)

Ophthalmology, Khyber Teaching Hospital MTI, Peshawar, PAK.

Hamza Haroon (H)

Surgery, Ayub Teaching Hospital, Abbottabad, PAK.

Obaid Ahmad (O)

Ophthalmology, Hayatabad Medical Complex MTI, Peshawar, PAK.

Muhammad Shahid Iqbal (MS)

Emergency Medicine, District Headquarter Hospital MTI, Bannu, PAK.

Zarafshan Zakir (Z)

Internal Medicine, Khyber Teaching Hospital MTI, Peshawar, PAK.

Maryum Khilji (M)

Ophthalmology, Khyber Teaching Hospital MTI, Peshawar, PAK.

Safina Tanveer (S)

Surgery, Khyber Teaching Hospital MTI, Peshawar, PAK.

Rao E Hassan (RE)

Orthopaedics and Trauma, Khyber Teaching Hospital MTI, Peshawar, PAK.

Classifications MeSH